EP3251660

BRISTOL-MYERS SQUIBB HOLDINGS IRELAND
Application Number
EP17175788A
Filing Date
Feb 24, 2011
Status
Revoked
Mar 22, 2024
Grant Date
Oct 16, 2019
External Links
Slate, Register

Biblio Summary

The patent EP3251660B1 was granted on Oct 16, 2019 by Bristol-Myers Squibb Holdings Ireland The patent is currently Revoked.

The table below shows 10 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

GENERICS UKJul 16, 2020ADMISSIBLE
STADAJul 16, 2020ADMISSIBLE
SANDOZJul 15, 2020ADMISSIBLE
INTAS PHARMACEUTICALS LTD.Jul 15, 2020WITHDRAWN
KRKA, D.D., NOVO MESTOJul 15, 2020WITHDRAWN
MEDICHEM S.A.Jul 14, 2020ADMISSIBLE
TEVAJul 14, 2020ADMISSIBLE
KUTZENBERGER WOLFF & PARTNERJul 13, 2020ADMISSIBLE
ZENTIVA K.S.Jul 10, 2020ADMISSIBLE
ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.Jul 2, 2020ADMISSIBLE

The table below shows the patents of Bristol-Myers Squibb Holdings Ireland that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP3246021Apixaban FormulationsNov 13, 201924
EP3257500Apixaban FormulationsOct 16, 201920
EP3017811Apixaban FormulationsDec 5, 201818